Gladius Capital Management’s Pfizer PFE Stock Holding History

Gladius Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-21,300	Closed	-$613K	–	397
2023 Q4	$613K	Sell	21,300 -55,300	-72%	-$1.67M	0.1%	99
2023 Q3	$2.54M	Buy	76,600 +15,900	+26%	+$562K	0.11%	107
2023 Q2	$2.23M	Buy	60,700 +17,000	+39%	+$662K	0.11%	80
2023 Q1	$1.78M	Buy	+43,700	New	+$1.89M	0.1%	90
2022 Q1	–	Sell	-2,800	Closed	-$166K	–	326
2021 Q4	$166K	Sell	2,800 -3,900	-58%	-$193K	0.01%	203
2021 Q3	$289K	Hold	6,700	–	–	0.02%	91
2021 Q2	$263K	Sell	6,700 -5,200	-44%	-$202K	0.02%	101
2021 Q1	$432K	Sell	11,900 -53,300	-82%	-$1.89M	0.02%	150
2020 Q4	$2.4M	Buy	65,200 +46,860	+256%	+$1.72M	0.12%	129
2020 Q3	$639K	Buy	+18,340	New	+$643K	0.06%	116
2020 Q1	–	Sell	-19,077	Closed	-$710K	–	170
2019 Q4	$710K	Sell	19,077 -352,036	-95%	-$12.5M	0.04%	138
2019 Q3	$12.7M	Buy	371,113 +352,036	+1,845%	+$12.8M	0.58%	37
2019 Q2	$793K	Buy	+19,077	New	+$758K	0.05%	110

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gladius Capital Management's PFE Position: Q4 2024 in Review

Gladius Capital Management sold out of Pfizer (PFE) in Q4 2024, closing a stake of 1,043 shares — an estimated $30.2K sold.

Gladius Capital Management first reported a position in PFE in Q2 2018 and held it in 22 quarters. The position peaked at $7.34M in Q4 2018. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

Gladius Capital Management reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
Gladius Capital Management sold 1,043 Pfizer shares in Q4 2024, an estimated $30.2K.
Gladius Capital Management first reported a position in Pfizer in Q2 2018 and held it in 22 quarters.
Gladius Capital Management's Pfizer position peaked at $7.34M in Q4 2018.
2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Gladius Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.